RRP is a rare condition characterised by the growth of benign tumours on and around the vocal cords. Credit: Andrey_Popov via Shutterstock.

US-based cell and gene therapy biotech Precigen will reduce its workforce by 20% and pause several programmes to focus on the potential commercialisation of its PRGN-2012 gene therapy for recurrent respiratory papillomatosis (RRP).

The company also announced that it will try to raise $30m in a public stock offering. It plans to give the option to buy up to $4.5m more in shares over the next 30 days. This move comes alongside a cost reduction strategy, which aims to streamline resources and focus on advancing PRGN-2012.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

As of June 2024, Precigen reported having $19.5m in cash. The funds from the offering and cost reduction strategies will support the company’s efforts to prepare PRGN-2012 for a potential market launch next year, with a rolling biologics licence application (BLA) submission expected in the latter half of 2024. 

This strategic shift involves the suspension of various clinical and preclinical programmes, except for the PRGN-2009 trials for certain cancers, and the PRGN-3006 programme for acute myeloid leukaemia (AML). The company also plans to shut down its Belgium-based ActoBio subsidiary and pause all preclinical activities. 

PRGN-2009 is being investigated in several Phase II studies, including in trials for recurrent/metastatic cervical cancer (NCT06157151) and newly diagnosed HPV-associated oropharyngeal cancer (NCT06223568) that are sponsored by the National Cancer Institute (NCI). However, enrolment for PRGN-2009 at non-NCI clinical sites will be paused. A Phase Ib trial of Its chimeric antigen receptor-T (CAR-T) therapy PRGN-3006 has completed enrolment for AML (NCT03927261), and Precigen plans to meet with the US Food and Drug Administration (FDA) to discuss the next steps. 

If everything goes to plan, PRGN-2012 will be Precigen’s first candidate to be approved. RRP is a rare condition characterised by the growth of benign tumours or papillomas in the respiratory tract. The condition is caused by human papillomavirus type 6 (HPV) or HPV type 11 (HPV 11), causing breathing difficulties. Based on the Gorilla Adenovector technology of the company’s AdenoVerse platform, PRGN-2012 can induce immune responses against HPV 6 or HPV 11-infected cells. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to GlobalData’s Pharma Intelligence Center, global sales of PRGN-2012 are forecast to reach $826m in 2030. 

GlobalData is the parent company of Pharmaceutical Technology. 

In the announcement accompanying the strategic move, Precigen’s CEO Helen Sabzevari said: “These prioritisation steps enhance our ability to rapidly prepare for the potential commercialisation of PRGN-2012, which, if approved, we believe has the safety, efficacy, and route of administration profile to be the first and best-in-class therapy for RRP patients.”